- The new NICE draft guideline on asthma management currently under consultation recommends leukotriene receptor antagonist (LTRA) tablets over combination inhaler therapy in a move to boost savings for the NHS.
- Newly diagnosed patients with asthma should be offered a short-acting beta2 agonist (SABA) to relieve symptoms as and when they occur.
- A low-dose inhaled corticosteroid (ICS) is suitable as maintenance therapy for patients with symptoms uncontrolled by SABA.
- If symptoms remain uncontrolled with ICS, patients should be offered an LTRA along with ICS before considering the combination (LABA + ICS) inhaler therapy.
- If LTRAs fail to work, adult and young patients can be switched to a combination inhaler. Children, however, should be referred to a specialist in such a scenario.
- NICE recommends initiating treatment with the 7 pence a day LTRA tablet earlier than the current practice. This could translate to a saving £3 million a year for the NHS.
- The clinical efficacy of both LTRAs and combination inhalers are strongly backed by evidence; however, the cost-effectiveness of LTRAs make them the primary choice.